Lebenthal Global Advisors LLC Makes New $1.22 Million Investment in Astrazeneca Plc $AZN

Key Points

• Lebenthal Global Advisors LLC acquired a new position in AstraZeneca (NYSE:AZN) in Q4, buying 13,279 shares valued at approximately $1.22 million.
• Several other institutions increased holdings—most notably TD Asset Management added 181,273 shares to hold 1,089,612 shares (≈$83.6M)—and about 20.35% of AZN is owned by hedge funds and other institutional investors.
• AstraZeneca opened at $192.35 with a market cap of $298.31 billion and a P/E of 33.13; the company paid a $1.595 dividend on March 23 (record/ex-dividend date Feb 20) and has a payout ratio of 74.83%.

Lebenthal Global Advisors LLC acquired a new position in Astrazeneca Plc (NYSE:AZN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 13,279 shares of the company's stock, valued at approximately $1,221,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cibc World Market Inc. lifted its holdings in shares of Astrazeneca by 21.5% in the 3rd quarter. Cibc World Market Inc. now owns 64,421 shares of the company's stock worth $4,942,000 after acquiring an additional 11,398 shares during the last quarter. TD Asset Management Inc lifted its holdings in shares of Astrazeneca by 20.0% in the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company's stock worth $83,595,000 after acquiring an additional 181,273 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its holdings in shares of Astrazeneca by 111.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company's stock worth $5,113,000 after acquiring an additional 35,148 shares during the last quarter. AMG National Trust Bank lifted its holdings in shares of Astrazeneca by 20.4% in the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company's stock worth $3,298,000 after acquiring an additional 7,289 shares during the last quarter. Finally, Oxbow Advisors LLC lifted its holdings in shares of Astrazeneca by 96.2% in the 3rd quarter. Oxbow Advisors LLC now owns 77,594 shares of the company's stock worth $5,953,000 after acquiring an additional 38,043 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Astrazeneca Price Performance

NYSE AZN opened at $192.35 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. The stock has a market cap of $298.31 billion, a price-to-earnings ratio of 33.13, a price-to-earnings-growth ratio of 1.47 and a beta of 0.35. Astrazeneca Plc has a one year low of $132.32 and a one year high of $212.71.

Astrazeneca Dividend Announcement

The company also recently disclosed a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were given a $1.595 dividend. The ex-dividend date of this dividend was Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca's payout ratio is presently 74.83%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on AZN shares. Weiss Ratings started coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They set a "buy (b)" rating for the company. Citigroup started coverage on shares of Astrazeneca in a report on Tuesday, January 27th. They set a "buy" rating for the company. Morgan Stanley reiterated an "overweight" rating on shares of Astrazeneca in a report on Wednesday, April 8th. Deutsche Bank Aktiengesellschaft reiterated a "sell" rating on shares of Astrazeneca in a report on Friday, February 6th. Finally, Wall Street Zen lowered shares of Astrazeneca from a "buy" rating to a "hold" rating in a report on Saturday, April 4th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $102.67.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.